茵胆平肝胶囊联合替诺福韦治疗慢性乙型肝炎肝硬化的临床效果  

Clinical effect of yindanpinggan capsule and tenofovir on chronic hepatitis B cirrhosis

作　　者：陈济永 CHEN Jiyong(Lianjiang County General Hospital,Fuzhou 350500,China)

机构地区：[1]连江县总医院,福建福州350500

出　　处：《临床医药实践》2025年第4期272-275,共4页Proceeding of Clinical Medicine

摘　　要：目的:探讨采用茵胆平肝胶囊联合替诺福韦治疗慢性乙型肝炎(CHB)肝硬化(LC)患者的临床效果。方法:选取连江县总医院2021年1月—2023年10月收治的CHB LC患者80例,按随机数表法分成观察组和对照组,每组40例。对照组采用替诺福韦治疗,观察组采用茵胆平肝胶囊联合替诺福韦治疗。比较两组临床疗效、肝功能指标、肝纤维化指标及不良反应。结果:观察组(95.0%)总有效率高于对照组(77.5%),差异有统计学意义(P<0.05)。治疗后两组γ-谷氨酰转移酶(GGT)、谷丙转氨酶(ALT)、总胆红素(TBiL)、谷草转氨酶(AST)、碱性磷酸酶(ALP)水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后两组层粘连蛋白(LN)、Ⅲ型前胶原肽氨基末端肽(PⅢNP)、Ⅳ型胶原(CⅣ)、血清透明质酸(HA)均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为10.0%,对照组为17.5%,两组比较差异无统计学意义(P>0.05)。结论:茵胆平肝胶囊联合替诺福韦治疗CHB LC,可提高临床疗效,改善患者肝功能指标和肝纤维化指标,具有较高安全性。Objective:To explore the effect of the clinical effect of YindanPinggan Capsule and tenofovir in patients with chronic hepatitis B(CHB)cirrhosis(LC).Methods:A total of 80 CHB LC patients from January 2021 to October 2023 who were admitted in Lianjiang County General Hospital were selected,and randomly divided into the observation group(n=40,YindanPinggan Capsule and tenofovir)and the control group(n=40,tenofovir).The clinical efficacy,liver function indicators,liver fibrosis indicators,and adverse reactions were compared in both groups.Results:The total effective rate of the observation group(95.0%)was higher than that of the control group(77.5%),with statistical significance(P<0.05).After treatment,the gamma glutamyltransferase(GGT),alanine aminotransferase(ALT),total bilirubin(TBiL),aspartate aminotransferase(AST),alkaline phosphatase(ALP)levels in both groups were decreased(P<0.05),and the observation group was lower than control group(P<0.05).After treatment,laminin(LN),type III procollagen peptide amino terminal peptide(PIIINP),type IV collagen(CIV),and serum hyaluronic acid(HA)levels in both groups were decreased(P<0.05),and the observation group was lower thanthe control group(P<0.05).The incidence of adverse reactions in the observation group was 10.0%,while that in the control group was 17.5%.There was no significant difference between the two groups(P>0.05).Conclusion:The use of yindanpinggan capsule and tenofovir in the treatment of CHB LC patients can improve clinical efficacy,liver function indicators and liver fibrosis indicators,and has high safety.

关 键 词：茵胆平肝胶囊 替诺福韦 慢性乙型肝炎 肝硬化 临床效果 

分 类 号：R575.2[医药卫生—消化系统]